Google AI
The Times Australia

Times Media

Notice to Long-term Integra Lifesciences Holdings Corporation (IART) Shareholders: Grabar Law Investigates Claims on Your Behalf

Philadelphia, Pennsylvania - Newsfile Corp. - March 24, 2025 - Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.



Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a "recall" of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off.

WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. $IART #IntegraLifeSciences

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

The issuer is solely responsible for the content of this announcement.

Times Magazine

The new ‘Apple Upgrade’ program has officially launched in the United States

TECH GIANT SHAKES UP FINANCING WITH KLARNA-BACKED SUBSCRIPTION LEASE CUPERTINO — Apple has offici...

Reel Rock 20 Returns to Australia This November and December

Reel Rock 20 returns to Australian and New Zealand screens this November as a part of the Reel Roc...

Still Want to Change Gears? The New Cars Keeping the Manual Alive in Australia

For decades, learning to drive meant mastering the clutch pedal, selecting the right gear and find...

Technology

The new ‘Apple Upgrade’ program has…

TECH GIANT SHAKES UP FINANCING WITH KLARNA-BACKED SUBSCRIPTION LEASE CUPERTINO — Apple has offici...

Local News

Fremantle Ports to trial project to…

Fremantle Ports has partnered with Byssal and DevelopmentWA to trial an innovative nature-based pilo...

Culture

From Restriction to Celebration: The Sydney R…

Sydney restaurant marks 10 years with a month-long celebration of artisan collaborations, from Amalf...

Travel

Korea Tourism Organization Invites Australian…

The Korea Tourism Organization (KTO) has launched Korea Unlocks More of You, a new national campai...

The Times Features

From Restriction to Celebration: The Sydney Restaurant …

Sydney restaurant marks 10 years with a month-long celebration of artisan collaborations, from Amalf...

Australia's Housing Market After Labor's Tax …

Several months after changes to property investment tax settings, Australia's housing market has d...

Why the US Federal Reserve's Interest Rate Decisio…

The United States Federal Reserve has left its benchmark interest rate unchanged at 3.5% to 3.75%...